Triple receptor-positive neuroendocrine breast cancer in a 32-year-old woman

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: ER positive; PR positive; HER2 positive; neuron-specific enolase positive; synaptophysin positive

She was stable on follow-up and was receiving adjuvant chest-wall radiation plus systemic chemotherapy and trastuzumab-based therapy.

PubMed CentralRead more →

Metastatic Breast Cancer With Liver Progression Treated Through Multiple Chemotherapy Lines

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: Initial tumor: ER 90%, HER2 3+, Ki67 15%. Liver metastasis: ER 30%

Metastatic Site: pleura, liver

After several periods of response and later liver progression, she remained on active treatment with pegylated liposomal doxorubicin.

PubMed CentralRead more →

Stage I Breast Cancer: Yanzi's Patient Story

Patient Info: Yanzi, 40s | Stage I

Years after her Stage I diagnosis, Yanzi had completed the other treatment and remained on hormone medication while coping with fear of recurrence.

Our Cancer StoriesRead more →

Metastatic Lobular Breast Cancer With Long-Term Disease Control Across Multiple Therapies

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: Initial tumor: ER negative, HER2 negative, Ki67 17%. 2006 recurrence: ER 40%

Metastatic Site: pleura, liver, skin, bone

She was alive on ongoing metronomic vinorelbine with substantial disease stabilization at the most recent follow-up.

PubMed CentralRead more →

Bilateral Breast Cancers Followed by Metastatic Disease and Long Eribulin Treatment

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: Left primary: ER 90%, HER2 FISH not amplified, Ki67 25%. Right primary: ER 90%

Metastatic Site: lung, pleura, liver, bone

After pelvic bone metastases appeared in 2017, she stopped eribulin, received pelvic radiation and remained on fulvestrant treatment.

PubMed CentralRead more →

Metastatic Breast Cancer Responding to Eribulin After Repeated Liver Progression

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: ER 100%, HER2 negative

Metastatic Site: bone, liver

Eribulin remained ongoing with repeated partial responses documented through 12 cycles and no need for dose reduction.

PubMed CentralRead more →

HER2-Positive Recurrent Breast Cancer Treated With Multiple Targeted and Local Therapies

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: 2008 recurrence: ER 80%, HER2 FISH amplified. 2011 recurrence: ER 80%

Metastatic Site: liver, skin

After 25 cycles of eribulin, treatment was still ongoing; nodal disease remained stable, while later imaging also noted new metabolic activity in the upper lung.

PubMed CentralRead more →

Stage IV Colorectal Adenocarcinoma: Patricia's Patient Story

Patient Info: Patricia, 50s | Stage IV

Living with Stage IV colorectal cancer after about 6.5 years of intermittent chemotherapy and multiple local treatments; on a treatment holiday while awaiting December 2024 scans.

Our Cancer StoriesRead more →

Stage IV rectal cancer treatment complicated by repeated heart-related side effects

Patient Info: Anonymized, Female | Stage IV

Biomarkers: p53 mutation

Metastatic Site: liver

After responding again to adapted chemotherapy and NanoKnife ablation, she had no evidence of active disease and had not restarted chemotherapy; ileostomy reversal was planned.

PubMed CentralRead more →

Severe but reversible neurologic side effects during 5-fluorouracil treatment for Stage IV colorectal cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Metastatic Site: liver

His confusion, dysarthria and ataxia resolved within 24 hours with intravenous hydration, and the MRI lesion resolved within 1 month. The cancer later progressed on restaging, prompting another treatment change.

PubMed CentralRead more →

Stage IV Breast Cancer: Lindsey's Patient Story

Patient Info: Lindsey Ballas, Female | Stage IV

Metastatic Site: Not reported

As of September 2017, Lindsey was living with Stage IV metastatic breast cancer on advanced targeted maintenance therapy every 3 weeks, with stable disease and continued work and family life.

Cleveland ClinicRead more →

Gastric cancer causes severe pulmonary hypertension that improves rapidly with imatinib

Patient Info: Anonymized, Female, 50s | Stage IV

She died from systemic metastatic gastric cancer 7 months after the pulmonary vascular presentation.

PubMed CentralRead more →

Metastatic Colorectal Cancer Treated With S-1 After 5-FU Cardiotoxicity

Patient Info: Anonymized, male, 60s

Biomarkers: RAS-mutant

After progression in the liver despite prior systemic and liver-directed treatment, he started S-1, oxaliplatin and bevacizumab; the first cycle caused no cardiac complication and treatment continued as an outpatient.

PubMed CentralRead more →

Finding Happiness Despite Stage IV Lung Cancer

Patient Info: Anonymized, 50s | Stage IV

More than a year after diagnosis, she remained in treatment for Stage IV lung cancer, with some therapies losing effectiveness as the cancer developed resistance.

Dana-FarberRead more →

HER2-Positive Inflammatory Breast Cancer: Trish's Patient Story

Patient Info: Trish Vickery, female, 50s

Biomarkers: HER2-positive

At 58, Trish was living an active life after treatment, including working, traveling, exercising, and rowing.

Dana-FarberRead more →

Breast cancer survivor finds comfort in quilting community

Patient Info: Michelle Hines, female

Michelle had been cancer-free since November 2015 at the time of the story.

MD AndersonRead more →

Stage IV ERBB2-Mutated Lung Cancer With Extensive Bone Metastases

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ERBB2 exon 20 insertion. A PIK3CA mutation was later detected at progression and considered a possible resistance mechanism.

Metastatic Site: bone

After progression on pemetrexed following several earlier treatment lines, she transitioned to hospice care.

PubMed CentralRead more →

Stage IV ERBB2-Mutated Lung Adenocarcinoma With Brain Metastases and Multiple Targeted Therapies

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: ERBB2 exon 20 insertion, exact sequence not specified. ERBB2 copy-number gain was identified during progression on afatinib.

Metastatic Site: brain, adrenal gland, liver

The final documented afatinib plus bevacizumab rechallenge produced a mixed response followed by liver progression after 3 months.

PubMed CentralRead more →

ERBB2-Mutated Metastatic Lung Adenocarcinoma With Leptomeningeal Progression

Patient Info: Anonymized, male

Biomarkers: ERBB2 A775_G776 insYVMA mutation with amplification

The final treatment produced a mixed systemic response, but leptomeningeal disease developed.

PubMed CentralRead more →

ERBB2-Mutated Metastatic Lung Adenocarcinoma With Treatment Intolerance and Progression

Patient Info: Anonymized, male

Biomarkers: ERBB2 A775_G776 insYVMA mutation

After poorly tolerated earlier regimens with stable disease, he developed symptomatic progression during 1 month of afatinib.

PubMed CentralRead more →

ERBB2-Mutated Metastatic Lung Adenocarcinoma Progressing Through Multiple Therapies

Patient Info: Anonymized, female

Biomarkers: ERBB2 mutation

The cancer progressed during afatinib, nivolumab and a later paclitaxel rechallenge.

PubMed CentralRead more →

ERBB2-Mutated Metastatic Lung Adenocarcinoma With Progression Across Multiple Regimens

Patient Info: Anonymized, male

Biomarkers: ERBB2 V777delinsVGSP mutation

After a brief period of stable disease on cisplatin plus docetaxel, the cancer progressed through erlotinib, gemcitabine and afatinib.

PubMed CentralRead more →

ERBB2-Mutated Metastatic Lung Adenocarcinoma With Limited Disease Control Across Multiple Therapies

Patient Info: Anonymized, female

Biomarkers: ERBB2 V776delinsVC mutation

After temporary stable disease when bevacizumab was added to chemotherapy, the cancer progressed on trastuzumab plus paclitaxel and then erlotinib.

PubMed CentralRead more →

ERBB2-Mutated Stage III Lung Cancer With Liver Recurrence and Multiple Lines of Therapy

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ERBB2 exon 20 insertion

Metastatic Site: liver

After 6 months of disease control on vinorelbine plus trastuzumab, the cancer progressed in all sites and she chose hospice care.

PubMed CentralRead more →